logo
Share SHARE
FONT-SIZE Plus   Neg

Synopsys Completes Acquisition Of ExpertIO

Technology company Synopsys, Inc. (SNPS) Monday announced that it acquired ExpertIO, Inc., an independent provider of verification IP, or VIP, for industry standard protocols. The terms of the deal were not disclosed.

Manoj Gandhi, General Manager of Synopsis Verification Group, commented, "By acquiring ExpertIO, Synopsys adds a new set of storage protocols to our expanding VIP portfolio, plus an experienced team of development experts to help us drive the next level of innovation in VIP technology."

ExpertIO's entire team of engineers will join Synopsys' Verification Group. The Founder and Chief Executive Officer of ExpertIO, Craig Stoops, will join the Synopsys team as a technical leader helping drive Synopsys' VIP roadmap.

With leading SoC designs deploying more complex protocols, VIP has become a critical component of the verification environment. VIP provides functional models of on- and off-chip protocols that verification engineers use to test all of the interfaces on an SoC before manufacturing.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT